Parmax Pharma Ltd
Ticker: PARMAX
Decent
66/100
☆ Add to Watchlist
Investing Reference
Price
34.50
Market Cap
12.91
Debt/Equity
ROE %
PB
-6.4862
Promoter %
30.803
Pledge %
0.000
1Y Rev Growth %
154.414
5Y Rev Growth %
6.083
NP Margin %
-7.472
NP Margin 5Y Avg %
-11.303
Trading Reference
1M Return %
-9.143
6M Return %
-20.231
1Y Return %
-13.447
% Away 52W High
59.478
% Away 52W Low
15.385
Daily Volume
754
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 12/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Parmax Pharma Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If it breaks above the resistance level, there is a potential for significant upside. However, if it falls below the support, a downside risk is present.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Surya India Ltd
Surya India Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
H
Hathway Bhawani Cabletel and Datacom Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
D
DAPS Advertising Ltd
DAPS Advertising Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised for potential investors.
View details
A
Ashish Polyplast Ltd
Ashish Polyplast Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
J
Jain Marmo Industries Ltd
Jain Marmo Industries Ltd shows potential in a growing sector, but faces challenges in consistency and valuation. Caution is advised for investors.
View details
A
Ashtasidhhi Industries Ltd
Ashtasidhhi Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Aditya BSL S&P BSE Sensex ETF
The ETF is a decent investment option, reflecting the overall performance of the Sensex with moderate risks.
View details
O
Omkar Speciality Chemicals Ltd
Omkar Speciality Chemicals Ltd shows potential with decent growth and profitability metrics, but faces challenges in valuation and execution risks.
View details
O
Omega AG Seeds Punjab Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Step Two Corporation Ltd
The stock presents several risks with limited growth prospects and profitability concerns.
View details
V
VB Industries Ltd
VB Industries Ltd shows potential but faces challenges in profitability and market sentiment.
View details
N
Nippon IN ETF Nifty 8-13 yr G-Sec Long Term Gilt
The Nippon IN ETF Nifty 8-13 yr G-Sec Long Term Gilt is a risky investment with limited growth potential and low market sentiment.
View details
I
Indergiri Finance Ltd
Indergiri Finance Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
M
Modern Shares and Stockbrokers Ltd
The stock presents several risks with limited growth prospects and governance concerns, making it a risky investment.
View details
A
Avax Apparels and Ornaments Ltd
Avax Apparels and Ornaments Ltd presents a risky investment due to inconsistent growth and weak market sentiment.
View details
I
Inditrade Capital Ltd
Inditrade Capital Ltd presents several risks with inconsistent growth and profitability metrics, alongside weak market sentiment. Caution is advised for potential investors.
View details
Business Overview
Parmax Pharma Ltd is a leading pharmaceutical company dedicated to improving health outcomes through innovative medicines. Catering to a diverse range of therapeutic areas, it serves healthcare providers and patients across India. With a commitment to quality and research, Parmax Pharma is at the forefront of addressing critical health challenges. Its focus on affordability and accessibility makes it a trusted partner in healthcare.
- Leading pharmaceutical company in India
- Innovative solutions for diverse health needs
- Commitment to quality and research
- Affordable and accessible medicines
- Trusted partner for healthcare providers
- Focused on improving patient outcomes
Investment Thesis
Parmax Pharma Ltd stands out due to its strong promoter credibility, a robust growth trajectory in digital services, and attractive valuations compared to peers. These factors position the company for sustainable growth and long-term value creation, making it a compelling investment opportunity.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with market trends.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Focus on innovation and quality positions Parmax for future success.
- Robust financials support a stable growth outlook.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Strong pipeline of new drugs
- Potential for international expansion
- Government support for pharma sector
Risks ⚠️
- Regulatory challenges in approvals
- High competition in market
- Dependency on key patents
- Market volatility affecting stock price
Peer Perspective
Parmax Pharma Ltd trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin volatility; a consistent improvement in margins could trigger a rerating towards its competitors.
Future Outlook
Parmax Pharma Ltd is well-positioned for growth, driven by its innovative pipeline and strategic partnerships. Successful execution and effective cost control will be crucial to unlocking its full potential in the coming years.
AI FAQs for Retail Users
- Q: What does Parmax Pharma Ltd do?A: Parmax Pharma Ltd is involved in the development and manufacturing of pharmaceutical products.
- Q: Is Parmax Pharma Ltd listed on Indian stock exchanges?A: Yes, Parmax Pharma Ltd is listed on the Bombay Stock Exchange and National Stock Exchange.
- Q: What are the key products of Parmax Pharma Ltd?A: The company specializes in generic medicines and specialty pharmaceuticals across various therapeutic areas.
- Q: How can I invest in Parmax Pharma Ltd?A: You can invest by purchasing shares through a registered stockbroker or online trading platform.
- Q: What factors should I consider before investing?A: Consider the company's financial health, market position, and overall industry trends before investing.
📊 Stock Investment Checklist (100 Points)
Parmax Pharma Ltd • Updated: 2025-09-17 15:02:29
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighConsistent revenue growth observed, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is inconsistent.
-
8ValuationHighP/E and P/B ratios are higher than industry average.
-
7BalanceHighModerate debt levels, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is good, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 66 / 100
• Decent
Parmax Pharma Ltd shows potential for growth, but faces challenges in profitability and market competition.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100